{"success":true,"data":{"pressRelease":{"id":"151952","rtpr_id":"nGNX60WMf0-20260924","ticker":"QNTM","exchange":"NASDAQ","all_tickers":["QNTM"],"title":"Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO","author":"Globe Newswire","published_at":"2026-09-24T12:00:00.718Z","article_body":"TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:\nQNTM) (FRA: 0K91) (“Quantum BioPharma”), today announced its licensee –\nUnbuzzd Wellness Inc. (the \"Company\" or \"Unbuzzd\"), the company behind\nunbuzzd™ (“unbuzzd”) — the scientifically-proven and game-changing\nbeverage proven to accelerate alcohol metabolism, restore mental clarity and\nreduce hangover symptoms, is pleased to announce the appointment of Mr.\nMichael Zapolin (“Zappy”) as CEO. This marks a pivotal milestone in the\nCompany. His mandate includes financing and listing Unbuzzd on a stock\nexchange and then executing a nationwide commercial marketing and product\nrollout in the United States.\n\nZappy began his career on Wall Street, becoming one of the youngest Vice\nPresidents at Bear Stearns, before emerging as an early internet entrepreneur\nbehind category-defining domains including Beer.com, Diamond.com and\nCreditCards.com. He later became an investor and futurist focused on emerging\nindustries, including psychedelics and next-generation wellness. Through\ninitiatives such as the Mushroom Investment Fund, he has backed companies\nacross the psychedelic economy, and he co-founded KetaMD, an at-home ketamine\ntelemedicine company acquired by Braxia Scientific in 2022. Zappy is a\ngraduate of Boston University and Harvard Business School’s Owner/President\nManagement Program. Playboy Magazine once dubbed Zappy Zapolin “The Man Who\nWants to Change the World with Psychedelics.” He now also wants to change\nthe world with unbuzzd.\n\nThe Company thanks Richard Buzbuzian who was Chief Executive Officer of the\nCompany and is now assisting in the transition to a publicly listed company\nscheduled to go effective in the next quarter.\n\n“In my experience, truly disruptive consumer products are built at the\nintersection of innovation, proven results and exceptional execution—and I\nbelieve unbuzzd has all three,” said Gerry David, Director of Unbuzzd\nWellness Inc. “The clinical validation behind unbuzzd gives us something\nextremely powerful to bring to consumers and retailers: a product with science\nsupporting what it says it can do. With Zappy’s entrepreneurial track\nrecord, ability to build brands and extensive network, I believe we now have\nthe leadership to take that foundation and turn unbuzzd into a significant\nconsumer brand. The opportunity in front of us is substantial, and I am\nextremely excited about what this team can accomplish.”\n\nClinically Validated, Science-backed Innovation\n\nunbuzzd stands apart in the wellness and recovery supplement landscape as\nthe only product backed by a peer-reviewed clinical study proving its\nefficacy in accelerating alcohol metabolism, restoring mental clarity, and\nreducing hangover symptoms. unbuzzd is available for sale on amazon.com and\nunbuzzd.com.\n\nThe peer-reviewed clinical study, which investigated the effects of unbuzzd on\nalcohol intoxication and alcohol metabolism, was published in the World\nJournal of Pharmaceutical and Medical Research (2026, volume 12, issue 3,\npages 446-467). The publication can be viewed by clicking the following link:\n\nhttps://zenodo.org/records/18873638\n\nAddressing Health-Conscious Consumer Demand\n\nThe shift toward better-for-you beverages continues to accelerate, with 70%\nof Americans actively seeking health benefits from their beverage choices\nand 72% of Gen Z consumers trying new beverages monthly. unbuzzd addresses\nthis consumer demand through a clean label approach—a proprietary\nblend of vitamins, minerals, and herbs developed by a world-class R&D team in\npharmacology and medicine. Unlike competitors targeting only hydration or\nhangover symptoms, unbuzzd combines both with metabolic science in\nconvenient ready-to-mix powder stick formats.\n\nScalable Platform for Multi-Channel Distribution\n\nThe Company's growth strategy targets an expansive retail footprint\nincluding pharmacies, liquor stores, supermarkets, mass merchandisers,\nconvenience stores, and college stores—a multi-channel\ndistribution approach mirroring successful nationwide rollouts by industry\nleaders. With national distribution capabilities and a scalable\nplatform for both retail and e-commerce, unbuzzd is positioned to capture\nsignificant share of the total addressable market for alcohol recovery\nand functional wellness beverages across North America and international\nmarkets.\n\n\"As unbuzzd moves to complete its listing on a stock exchange, we are pleased\nto announce Mr. Zapolin to lead the team,\" commented Dr. Eric Hoskins,\nDirector. \"With the functional beverage market on track to exceed $198\nbillion and consumer demand for clinically\nvalidated, better-for-you products at an all-time high and Mr. Zapolin’s\nextensive network, the timing is excellent.\"\n\n\"As an advocate for alternative health treatments, I got very excited about\nunbuzzd a couple of years ago when I heard that the science team had cracked\nthe code” commented Mr. Zapolin, CEO, Unbuzzd Wellness. “We’ve needed\nsomething like this for as long as alcohol has been part of our society.”\n\nMr. Zapolin continued, “the team includes some of the most brilliant people\nfrom the beverage industry and scientific community. I believe unbuzzd has the\npotential to help millions of lives, and I’m honored to help bring it\nforward.”\n\nAbout Unbuzzd Wellness Inc.\n\nUnbuzzd Wellness Inc., a non-trading but fully reporting public issuer, stands\nas a pioneering force in the wellness and recovery supplement landscape.\nunbuzzd has been developed by a world-class R&D team in pharmacology and\nmedicine, with a commitment to innovation and quality. A proprietary blend of\nvitamins, minerals, and herbs, unbuzzd helps your body process alcohol faster,\nrestore mental alertness, and improve cognition so you can drink responsibly\nand drink refreshingly. unbuzzd appeals to a broad target audience of alcohol\nconsumers who want to have a good time, be in control, and still feel great\nthe next day.\n\nScientifically backed by a recently completed double-blind, randomized,\nplacebo-controlled crossover design clinical trial, unbuzzd dramatically\naccelerates alcohol metabolism, speeds the reduction of blood alcohol\nconcentration (\"BAC\"), restores mental clarity, and reduces the symptoms of\nintoxication, impairment and hangover. Key findings from the clinical trial\ninclude:\n* Accelerated Alcohol Metabolism: unbuzzd dramatically and rapidly reduced\nblood alcohol concentration in study participants. The rate at which BAC was\nlowered was, on average for most participants, more than 40 percent faster\nwithin 30 minutes of consuming unbuzzd compared to control subjects.\n* Rapid Improvements in Alertness: Study participants reported statistically\nsignificant improvement in alertness as soon as 30 minutes after consuming\nunbuzzd. Participants felt more alert and made fewer cognitive errors within\n30 minutes of consuming unbuzzd, significantly outperforming placebo results.\n* Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd\nlessened the elevation in heart rate and the drop in blood pressure that often\naccompanies alcohol intoxication, stabilizing both. This result was\nstatistically significant.\n* Reduced Perceived Impairment and Mental Fatigue: unbuzzd helped alleviate\nperceived impairment and mental fatigue caused by alcohol intoxication.\n* Hangover Relief: Participants in this study noted a statistically\nsignificant reduction in hangover symptoms. This included reduced cognitive\nand physical impairment, and reduced headache compared to placebo results, at\nboth four hours (67 percent reduction in headache severity) and eight hours\nafter consuming unbuzzd.\n* No Side Effects: unbuzzd was well-tolerated by all study participants, with\nno reported adverse side effects.\nThe full press release of the clinical trial can be found here\n(https://www.globenewswire.com/Tracker?data=4Oq-EkomVVrST0O9CvSRCjq2jeP9tk99RS6bbEqNqhhK7GVKHEeZvv_f7h9tC6f14ZIOjzKbfAKiRqngBVDlN7n-9UCZNbhtvmPSQkgd9_vSiTJYBfELvkwUqGEvu31HQlaoyR_MRIpzcyeHRSnWuU9mC8SOV-zxGimITjot_lnL4Jz7JLacDpW7PoHDuldWgunRdVP6bkI_5JbLMsJjds-1fb1Mmi6HvP6Y_sLplV0=).\n\nunbuzzd ready-to-mix powder sticks are available in 3-pack, 8-pack, and\n18-pack formats at https://unbuzzd.com.\n\nIndividual results may vary. unbuzzd is a dietary supplement. Consuming\nunbuzzd after alcohol ingestion does not permit you to operate a vehicle.\nDrink responsibly. DO NOT DRINK AND DRIVE.\n\nFor additional information, please contact:\nMichael “Zappy” Zapolin\nChief Executive Officer\nT: (617) 447-9012 \nE: zappy@unbuzzd.com\n\n\n\n8-pack, 18-pack, and 3-pack formats of the unbuzzd ready-to-mix powder sticks\nTo view an enhanced version of this graphic, please visit: link\n(https://www.globenewswire.com/Tracker?data=GAHQBVOzrh6IaYakj5QuMe0Qrjb5rYLM55KZZRnfAk-ypHPQ1mGR_QyvoPOB0G_5S4WMQRwT_2F3eQRKNDf4F29NiSD29QZGPl2h7tLeopw7pg1JOrjTi9fTCtZ3zUY_PTavdCl4jggrGpapvXytxQ==)\n\nAbout Quantum BioPharma Ltd.\n\nQuantum is a biopharmaceutical company dedicated to building a portfolio of\ninnovative assets and biotech solutions for the treatment of challenging\nneurodegenerative and metabolic disorders and alcohol misuse disorders with\ndrug candidates in different stages of development. Through its wholly owned\nsubsidiary, Lucid Psycheceuticals Inc. (\"Lucid\"), Quantum is focused on the\nresearch and development of its lead compound, Lucid-MS. Lucid-MS is a\npatented new chemical entity shown to prevent and reverse myelin degradation,\nthe underlying mechanism of multiple sclerosis, in preclinical models. Quantum\ninvented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc.\n(\"Unbuzzd\") (formerly, Celly Nutrition Corp.), led by industry veterans.\nQuantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The\nagreement with Unbuzzd also includes royalty payments of 7% of sales from\nunbuzzd™ until payments to Quantum total $250 million. Once $250 million is\nreached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the\nrights to develop similar products or alternative formulations specifically\nfor pharmaceutical and medical uses.\n\nFor more information visit www.quantumbiopharma.com.\n\nForward-Looking Information\n\nThis news release contains “forward-looking information” and\n“forward-looking statements” (collectively, “forward-looking\ninformation”) within the meaning of applicable Canadian securities laws.\nForward-looking information is generally, but not always, identified by words\nsuch as “anticipates,” “believes,” “expects,” “intends,”\n“plans,” “potential,” “proposes,” “estimates,” “may,”\n“could,” “would,” “will” and similar expressions. Forward-looking\ninformation in this news release includes, but is not limited to, statements\nregarding the Company’s plans to seek financing and a listing of its\nsecurities on a stock exchange; the timing and completion of any such\nfinancing or listing; the Company’s planned nationwide commercial marketing\nand product rollout in the United States; expansion of retail, e-commerce and\nother distribution channels; the Company’s ability to scale its platform and\noperations; potential market opportunities and consumer demand for unbuzzd;\nand the Company’s expectations regarding the future commercialization,\ndistribution, adoption and performance of unbuzzd.\n\nForward-looking information is based on management’s current expectations,\nestimates, projections, assumptions and beliefs as of the date of this news\nrelease, including assumptions regarding the availability of financing on\nacceptable terms; the Company’s ability to satisfy applicable regulatory,\nsecurities exchange and other requirements for a listing; favourable market\nand economic conditions; the continued availability and performance of key\npersonnel, suppliers, distributors and strategic partners; the Company’s\nability to manufacture and distribute products at commercial scale; continued\nconsumer demand for functional wellness products; the accuracy and\napplicability of market data and third-party research; and the Company’s\nability to execute its business, marketing and commercialization plans.\n\nForward-looking information is subject to known and unknown risks,\nuncertainties and other factors that may cause actual results, performance or\nachievements to differ materially from those expressed or implied by such\nforward-looking information. These risks and uncertainties include, among\nothers, the Company’s early stage of commercialization; the availability and\ncost of capital; the risk that a financing or stock exchange listing may be\ndelayed, completed on different terms or not completed at all; regulatory\nrequirements applicable to the Company, its products, product claims,\nlabelling, marketing and distribution; changes in applicable laws and\nregulations; the Company’s ability to protect its intellectual property;\ncompetition and the introduction of competing products; reliance on key\npersonnel, suppliers, manufacturers, distributors and other third parties;\nmanufacturing, supply-chain and distribution disruptions; product liability\nand consumer acceptance risks; the ability to achieve anticipated sales,\ndistribution and market penetration; and general economic, financial market\nand industry conditions.\n\nAlthough the Company believes that the assumptions and expectations reflected\nin such forward-looking information are reasonable, there can be no assurance\nthat they will prove to be correct. Readers are cautioned not to place undue\nreliance on forward-looking information. Actual results and future events\ncould differ materially from those anticipated in such information.\nThe forward-looking information contained in this news release is made as of\nthe date hereof. Except as required by applicable securities laws, the Company\nundertakes no obligation to update or revise any forward-looking information,\nwhether as a result of new information, future events or otherwise.\n\nThe Company does not represent that unbuzzd prevents, treats or cures any\ndisease or medical condition. unbuzzd is a dietary supplement, and statements\nregarding its effects are subject to the limitations described in the\nreferenced clinical study and may not apply to every individual. The U.S. Food\nand Drug Administration, Health Canada and other similar regulatory\nauthorities have not evaluated or approved unbuzzd for the diagnosis,\ntreatment, cure or prevention of disease. Individual results may vary.\nConsuming unbuzzd after alcohol ingestion does not make it safe or lawful to\noperate a motor vehicle or engage in any activity requiring sobriety. Drink\nresponsibly. DO NOT DRINK AND DRIVE.\n\nContacts:\n\nInvestor Relations\nRobert Guzman, Investor Relations \nEmail: Rob@QuantumBioPharma.com   \nTelephone: (833) 304-0323\nGeneral Inquiries: info@QuantumBioPharma.com\n\nA photo accompanying this announcement is available at\nhttps://www.globenewswire.com/NewsRoom/AttachmentNg/59611581-4786-49a7-918d-b18dd32889b0\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/8b9aab62-d5e1-47c2-a1ce-834c390552e6)\nunbuzzd product image \n(https://www.globenewswire.com/NewsRoom/AttachmentNg/59611581-4786-49a7-918d-b18dd32889b0/en)\n8-pack, 18-pack, and 3-pack formats of the unbuzzd ready-to-mix powder sticks\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX60WMf0-20260924","title":"Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO","author":"Globe Newswire","ticker":"QNTM","created":"2026-09-24T12:00:00.718Z","tickers":["QNTM"],"exchange":"NASDAQ","article_body":"TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:\nQNTM) (FRA: 0K91) (“Quantum BioPharma”), today announced its licensee –\nUnbuzzd Wellness Inc. (the \"Company\" or \"Unbuzzd\"), the company behind\nunbuzzd™ (“unbuzzd”) — the scientifically-proven and game-changing\nbeverage proven to accelerate alcohol metabolism, restore mental clarity and\nreduce hangover symptoms, is pleased to announce the appointment of Mr.\nMichael Zapolin (“Zappy”) as CEO. This marks a pivotal milestone in the\nCompany. His mandate includes financing and listing Unbuzzd on a stock\nexchange and then executing a nationwide commercial marketing and product\nrollout in the United States.\n\nZappy began his career on Wall Street, becoming one of the youngest Vice\nPresidents at Bear Stearns, before emerging as an early internet entrepreneur\nbehind category-defining domains including Beer.com, Diamond.com and\nCreditCards.com. He later became an investor and futurist focused on emerging\nindustries, including psychedelics and next-generation wellness. Through\ninitiatives such as the Mushroom Investment Fund, he has backed companies\nacross the psychedelic economy, and he co-founded KetaMD, an at-home ketamine\ntelemedicine company acquired by Braxia Scientific in 2022. Zappy is a\ngraduate of Boston University and Harvard Business School’s Owner/President\nManagement Program. Playboy Magazine once dubbed Zappy Zapolin “The Man Who\nWants to Change the World with Psychedelics.” He now also wants to change\nthe world with unbuzzd.\n\nThe Company thanks Richard Buzbuzian who was Chief Executive Officer of the\nCompany and is now assisting in the transition to a publicly listed company\nscheduled to go effective in the next quarter.\n\n“In my experience, truly disruptive consumer products are built at the\nintersection of innovation, proven results and exceptional execution—and I\nbelieve unbuzzd has all three,” said Gerry David, Director of Unbuzzd\nWellness Inc. “The clinical validation behind unbuzzd gives us something\nextremely powerful to bring to consumers and retailers: a product with science\nsupporting what it says it can do. With Zappy’s entrepreneurial track\nrecord, ability to build brands and extensive network, I believe we now have\nthe leadership to take that foundation and turn unbuzzd into a significant\nconsumer brand. The opportunity in front of us is substantial, and I am\nextremely excited about what this team can accomplish.”\n\nClinically Validated, Science-backed Innovation\n\nunbuzzd stands apart in the wellness and recovery supplement landscape as\nthe only product backed by a peer-reviewed clinical study proving its\nefficacy in accelerating alcohol metabolism, restoring mental clarity, and\nreducing hangover symptoms. unbuzzd is available for sale on amazon.com and\nunbuzzd.com.\n\nThe peer-reviewed clinical study, which investigated the effects of unbuzzd on\nalcohol intoxication and alcohol metabolism, was published in the World\nJournal of Pharmaceutical and Medical Research (2026, volume 12, issue 3,\npages 446-467). The publication can be viewed by clicking the following link:\n\nhttps://zenodo.org/records/18873638\n\nAddressing Health-Conscious Consumer Demand\n\nThe shift toward better-for-you beverages continues to accelerate, with 70%\nof Americans actively seeking health benefits from their beverage choices\nand 72% of Gen Z consumers trying new beverages monthly. unbuzzd addresses\nthis consumer demand through a clean label approach—a proprietary\nblend of vitamins, minerals, and herbs developed by a world-class R&D team in\npharmacology and medicine. Unlike competitors targeting only hydration or\nhangover symptoms, unbuzzd combines both with metabolic science in\nconvenient ready-to-mix powder stick formats.\n\nScalable Platform for Multi-Channel Distribution\n\nThe Company's growth strategy targets an expansive retail footprint\nincluding pharmacies, liquor stores, supermarkets, mass merchandisers,\nconvenience stores, and college stores—a multi-channel\ndistribution approach mirroring successful nationwide rollouts by industry\nleaders. With national distribution capabilities and a scalable\nplatform for both retail and e-commerce, unbuzzd is positioned to capture\nsignificant share of the total addressable market for alcohol recovery\nand functional wellness beverages across North America and international\nmarkets.\n\n\"As unbuzzd moves to complete its listing on a stock exchange, we are pleased\nto announce Mr. Zapolin to lead the team,\" commented Dr. Eric Hoskins,\nDirector. \"With the functional beverage market on track to exceed $198\nbillion and consumer demand for clinically\nvalidated, better-for-you products at an all-time high and Mr. Zapolin’s\nextensive network, the timing is excellent.\"\n\n\"As an advocate for alternative health treatments, I got very excited about\nunbuzzd a couple of years ago when I heard that the science team had cracked\nthe code” commented Mr. Zapolin, CEO, Unbuzzd Wellness. “We’ve needed\nsomething like this for as long as alcohol has been part of our society.”\n\nMr. Zapolin continued, “the team includes some of the most brilliant people\nfrom the beverage industry and scientific community. I believe unbuzzd has the\npotential to help millions of lives, and I’m honored to help bring it\nforward.”\n\nAbout Unbuzzd Wellness Inc.\n\nUnbuzzd Wellness Inc., a non-trading but fully reporting public issuer, stands\nas a pioneering force in the wellness and recovery supplement landscape.\nunbuzzd has been developed by a world-class R&D team in pharmacology and\nmedicine, with a commitment to innovation and quality. A proprietary blend of\nvitamins, minerals, and herbs, unbuzzd helps your body process alcohol faster,\nrestore mental alertness, and improve cognition so you can drink responsibly\nand drink refreshingly. unbuzzd appeals to a broad target audience of alcohol\nconsumers who want to have a good time, be in control, and still feel great\nthe next day.\n\nScientifically backed by a recently completed double-blind, randomized,\nplacebo-controlled crossover design clinical trial, unbuzzd dramatically\naccelerates alcohol metabolism, speeds the reduction of blood alcohol\nconcentration (\"BAC\"), restores mental clarity, and reduces the symptoms of\nintoxication, impairment and hangover. Key findings from the clinical trial\ninclude:\n* Accelerated Alcohol Metabolism: unbuzzd dramatically and rapidly reduced\nblood alcohol concentration in study participants. The rate at which BAC was\nlowered was, on average for most participants, more than 40 percent faster\nwithin 30 minutes of consuming unbuzzd compared to control subjects.\n* Rapid Improvements in Alertness: Study participants reported statistically\nsignificant improvement in alertness as soon as 30 minutes after consuming\nunbuzzd. Participants felt more alert and made fewer cognitive errors within\n30 minutes of consuming unbuzzd, significantly outperforming placebo results.\n* Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd\nlessened the elevation in heart rate and the drop in blood pressure that often\naccompanies alcohol intoxication, stabilizing both. This result was\nstatistically significant.\n* Reduced Perceived Impairment and Mental Fatigue: unbuzzd helped alleviate\nperceived impairment and mental fatigue caused by alcohol intoxication.\n* Hangover Relief: Participants in this study noted a statistically\nsignificant reduction in hangover symptoms. This included reduced cognitive\nand physical impairment, and reduced headache compared to placebo results, at\nboth four hours (67 percent reduction in headache severity) and eight hours\nafter consuming unbuzzd.\n* No Side Effects: unbuzzd was well-tolerated by all study participants, with\nno reported adverse side effects.\nThe full press release of the clinical trial can be found here\n(https://www.globenewswire.com/Tracker?data=4Oq-EkomVVrST0O9CvSRCjq2jeP9tk99RS6bbEqNqhhK7GVKHEeZvv_f7h9tC6f14ZIOjzKbfAKiRqngBVDlN7n-9UCZNbhtvmPSQkgd9_vSiTJYBfELvkwUqGEvu31HQlaoyR_MRIpzcyeHRSnWuU9mC8SOV-zxGimITjot_lnL4Jz7JLacDpW7PoHDuldWgunRdVP6bkI_5JbLMsJjds-1fb1Mmi6HvP6Y_sLplV0=).\n\nunbuzzd ready-to-mix powder sticks are available in 3-pack, 8-pack, and\n18-pack formats at https://unbuzzd.com.\n\nIndividual results may vary. unbuzzd is a dietary supplement. Consuming\nunbuzzd after alcohol ingestion does not permit you to operate a vehicle.\nDrink responsibly. DO NOT DRINK AND DRIVE.\n\nFor additional information, please contact:\nMichael “Zappy” Zapolin\nChief Executive Officer\nT: (617) 447-9012 \nE: zappy@unbuzzd.com\n\n\n\n8-pack, 18-pack, and 3-pack formats of the unbuzzd ready-to-mix powder sticks\nTo view an enhanced version of this graphic, please visit: link\n(https://www.globenewswire.com/Tracker?data=GAHQBVOzrh6IaYakj5QuMe0Qrjb5rYLM55KZZRnfAk-ypHPQ1mGR_QyvoPOB0G_5S4WMQRwT_2F3eQRKNDf4F29NiSD29QZGPl2h7tLeopw7pg1JOrjTi9fTCtZ3zUY_PTavdCl4jggrGpapvXytxQ==)\n\nAbout Quantum BioPharma Ltd.\n\nQuantum is a biopharmaceutical company dedicated to building a portfolio of\ninnovative assets and biotech solutions for the treatment of challenging\nneurodegenerative and metabolic disorders and alcohol misuse disorders with\ndrug candidates in different stages of development. Through its wholly owned\nsubsidiary, Lucid Psycheceuticals Inc. (\"Lucid\"), Quantum is focused on the\nresearch and development of its lead compound, Lucid-MS. Lucid-MS is a\npatented new chemical entity shown to prevent and reverse myelin degradation,\nthe underlying mechanism of multiple sclerosis, in preclinical models. Quantum\ninvented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc.\n(\"Unbuzzd\") (formerly, Celly Nutrition Corp.), led by industry veterans.\nQuantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The\nagreement with Unbuzzd also includes royalty payments of 7% of sales from\nunbuzzd™ until payments to Quantum total $250 million. Once $250 million is\nreached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the\nrights to develop similar products or alternative formulations specifically\nfor pharmaceutical and medical uses.\n\nFor more information visit www.quantumbiopharma.com.\n\nForward-Looking Information\n\nThis news release contains “forward-looking information” and\n“forward-looking statements” (collectively, “forward-looking\ninformation”) within the meaning of applicable Canadian securities laws.\nForward-looking information is generally, but not always, identified by words\nsuch as “anticipates,” “believes,” “expects,” “intends,”\n“plans,” “potential,” “proposes,” “estimates,” “may,”\n“could,” “would,” “will” and similar expressions. Forward-looking\ninformation in this news release includes, but is not limited to, statements\nregarding the Company’s plans to seek financing and a listing of its\nsecurities on a stock exchange; the timing and completion of any such\nfinancing or listing; the Company’s planned nationwide commercial marketing\nand product rollout in the United States; expansion of retail, e-commerce and\nother distribution channels; the Company’s ability to scale its platform and\noperations; potential market opportunities and consumer demand for unbuzzd;\nand the Company’s expectations regarding the future commercialization,\ndistribution, adoption and performance of unbuzzd.\n\nForward-looking information is based on management’s current expectations,\nestimates, projections, assumptions and beliefs as of the date of this news\nrelease, including assumptions regarding the availability of financing on\nacceptable terms; the Company’s ability to satisfy applicable regulatory,\nsecurities exchange and other requirements for a listing; favourable market\nand economic conditions; the continued availability and performance of key\npersonnel, suppliers, distributors and strategic partners; the Company’s\nability to manufacture and distribute products at commercial scale; continued\nconsumer demand for functional wellness products; the accuracy and\napplicability of market data and third-party research; and the Company’s\nability to execute its business, marketing and commercialization plans.\n\nForward-looking information is subject to known and unknown risks,\nuncertainties and other factors that may cause actual results, performance or\nachievements to differ materially from those expressed or implied by such\nforward-looking information. These risks and uncertainties include, among\nothers, the Company’s early stage of commercialization; the availability and\ncost of capital; the risk that a financing or stock exchange listing may be\ndelayed, completed on different terms or not completed at all; regulatory\nrequirements applicable to the Company, its products, product claims,\nlabelling, marketing and distribution; changes in applicable laws and\nregulations; the Company’s ability to protect its intellectual property;\ncompetition and the introduction of competing products; reliance on key\npersonnel, suppliers, manufacturers, distributors and other third parties;\nmanufacturing, supply-chain and distribution disruptions; product liability\nand consumer acceptance risks; the ability to achieve anticipated sales,\ndistribution and market penetration; and general economic, financial market\nand industry conditions.\n\nAlthough the Company believes that the assumptions and expectations reflected\nin such forward-looking information are reasonable, there can be no assurance\nthat they will prove to be correct. Readers are cautioned not to place undue\nreliance on forward-looking information. Actual results and future events\ncould differ materially from those anticipated in such information.\nThe forward-looking information contained in this news release is made as of\nthe date hereof. Except as required by applicable securities laws, the Company\nundertakes no obligation to update or revise any forward-looking information,\nwhether as a result of new information, future events or otherwise.\n\nThe Company does not represent that unbuzzd prevents, treats or cures any\ndisease or medical condition. unbuzzd is a dietary supplement, and statements\nregarding its effects are subject to the limitations described in the\nreferenced clinical study and may not apply to every individual. The U.S. Food\nand Drug Administration, Health Canada and other similar regulatory\nauthorities have not evaluated or approved unbuzzd for the diagnosis,\ntreatment, cure or prevention of disease. Individual results may vary.\nConsuming unbuzzd after alcohol ingestion does not make it safe or lawful to\noperate a motor vehicle or engage in any activity requiring sobriety. Drink\nresponsibly. DO NOT DRINK AND DRIVE.\n\nContacts:\n\nInvestor Relations\nRobert Guzman, Investor Relations \nEmail: Rob@QuantumBioPharma.com   \nTelephone: (833) 304-0323\nGeneral Inquiries: info@QuantumBioPharma.com\n\nA photo accompanying this announcement is available at\nhttps://www.globenewswire.com/NewsRoom/AttachmentNg/59611581-4786-49a7-918d-b18dd32889b0\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/8b9aab62-d5e1-47c2-a1ce-834c390552e6)\nunbuzzd product image \n(https://www.globenewswire.com/NewsRoom/AttachmentNg/59611581-4786-49a7-918d-b18dd32889b0/en)\n8-pack, 18-pack, and 3-pack formats of the unbuzzd ready-to-mix powder sticks\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-24T12:00:00.778026953Z","server_sent_at_ms":1790251200778},"received_at":"2026-09-24T12:00:00.839Z","source_url":null},"analysis":{"id":"140764","press_release_id":"151952","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Event occurs at licensee, not the filer; direct financial benefit to QNTM is indirect and uncertain","Unbuzzd is a non-trading issuer; planned stock exchange listing and financing may be delayed or not completed","unbuzzd is a dietary supplement not evaluated or approved by FDA/Health Canada for disease claims","Promotional tone with market-size claims (functional beverage market >$198 billion) not tied to company-specific revenue"],"eventType":"executive_change","narrative":"Quantum BioPharma's licensee Unbuzzd Wellness appointed Michael \"Zappy\" Zapolin as CEO, with a mandate to finance and list the company on a stock exchange and execute a nationwide US rollout of the unbuzzd alcohol-metabolism beverage.\n\nQuantum BioPharma retains 19.48% ownership of Unbuzzd and a 7% royalty on sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.\n\nThe release also cites a peer-reviewed clinical trial showing BAC reduction more than 40% faster within 30 minutes and a 67% reduction in headache severity at four hours; unbuzzd is sold as a dietary supplement on Amazon and unbuzzd.com.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Licensee leadership change and planned listing could accelerate the royalty path for QNTM's 19.48%-owned unbuzzd stake."},"keyFigures":{"customDimensions":{"royalty_rate":"7% of sales until payments total $250 million, then 3% in perpetuity","qntm_ownership_pct":"19.48%","bac_reduction_speed":">40% faster BAC reduction within 30 minutes vs control","headache_severity_reduction":"67% at four hours"}},"quotedText":"truly disruptive consumer products are built at the intersection of innovation, proven results and exceptional execution","namedEntities":{"people":[{"name":"Michael Zapolin (\"Zappy\")","role":"CEO, Unbuzzd Wellness Inc."},{"name":"Richard Buzbuzian","role":"former CEO, Unbuzzd Wellness Inc."},{"name":"Gerry David","role":"Director, Unbuzzd Wellness Inc."},{"name":"Dr. Eric Hoskins","role":"Director, Unbuzzd Wellness Inc."},{"name":"Robert Guzman","role":"Investor Relations, Quantum BioPharma"}],"products":["unbuzzd","Lucid-MS","KetaMD"],"companies":[{"name":"Quantum BioPharma Ltd.","ticker":"QNTM","relationship":"filer/licensor"},{"name":"Unbuzzd Wellness Inc.","relationship":"licensee (19.48% QNTM-owned)"},{"name":"Lucid Psycheceuticals Inc.","relationship":"QNTM subsidiary"},{"name":"Braxia Scientific","relationship":"acquirer of KetaMD (Zapolin prior venture)"}],"dollarAmounts":[{"amount":"$250 million","context":"cumulative royalty payments to QNTM before rate drops to 3%"},{"amount":"$198 billion","context":"projected functional beverage market size"}]},"materialImpact":{"score":2,"reasoning":"The CEO appointment is at Unbuzzd Wellness, a licensee in which Quantum BioPharma holds 19.48% and a 7% royalty stream — not at the filer itself. A planned listing and US rollout of the licensee could eventually benefit QNTM via royalties, but this is a promotional update with no immediate financial impact."},"tickerRelevance":{"others":[],"primary":"QNTM"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"micro-cap biotech","eventGravity":"CEO change at non-trading licensee","issuerAuthored":true,"retailFavoriteBoost":"wellness/psychedelic-adjacent narrative may attract retail attention"}},"event_type":"executive_change","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"Quantum BioPharma's licensee Unbuzzd Wellness appointed Michael \"Zappy\" Zapolin as CEO, with a mandate to finance and list the company on a stock exchange and execute a nationwide US rollout of the unbuzzd alcohol-metabolism beverage.\n\nQuantum BioPharma retains 19.48% ownership of Unbuzzd and a 7% royalty on sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.\n\nThe release also cites a peer-reviewed clinical trial showing BAC reduction more than 40% faster within 30 minutes and a 67% reduction in headache severity at four hours; unbuzzd is sold as a dietary supplement on Amazon and unbuzzd.com.","key_figures":{"customDimensions":{"royalty_rate":"7% of sales until payments total $250 million, then 3% in perpetuity","qntm_ownership_pct":"19.48%","bac_reduction_speed":">40% faster BAC reduction within 30 minutes vs control","headache_severity_reduction":"67% at four hours"}},"named_entities":{"people":[{"name":"Michael Zapolin (\"Zappy\")","role":"CEO, Unbuzzd Wellness Inc."},{"name":"Richard Buzbuzian","role":"former CEO, Unbuzzd Wellness Inc."},{"name":"Gerry David","role":"Director, Unbuzzd Wellness Inc."},{"name":"Dr. Eric Hoskins","role":"Director, Unbuzzd Wellness Inc."},{"name":"Robert Guzman","role":"Investor Relations, Quantum BioPharma"}],"products":["unbuzzd","Lucid-MS","KetaMD"],"companies":[{"name":"Quantum BioPharma Ltd.","ticker":"QNTM","relationship":"filer/licensor"},{"name":"Unbuzzd Wellness Inc.","relationship":"licensee (19.48% QNTM-owned)"},{"name":"Lucid Psycheceuticals Inc.","relationship":"QNTM subsidiary"},{"name":"Braxia Scientific","relationship":"acquirer of KetaMD (Zapolin prior venture)"}],"dollarAmounts":[{"amount":"$250 million","context":"cumulative royalty payments to QNTM before rate drops to 3%"},{"amount":"$198 billion","context":"projected functional beverage market size"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-24T12:00:13.194Z","global_importance":15,"audience_relevance":20,"importance_components":{"tickerTier":"micro-cap biotech","eventGravity":"CEO change at non-trading licensee","issuerAuthored":true,"retailFavoriteBoost":"wellness/psychedelic-adjacent narrative may attract retail attention"}},"durationMs":7878,"modelName":"glm-5.3-flashx"}}